United States Patent 11,433,059: Scope, Claim Construction, and Alpelisib Patent Landscape
U.S. Patent No. 11,433,059 protects oral administration of BYL719, now known as alpelisib, to patients with PIK3CA-related overgrowth spectrum disorders, including CLOVES syndrome and Klippel-Trenaunay syndrome. The claims are directed to patient selection, disease biology, rapamycin nonresponse, dosing, and reversal of multi-organ or multi-tissue overgrowth. The patent is a method-of-use asset rather than a composition-of-matter patent and is most relevant to Vijoice commercialization, PROS treatment protocols, and generic or off-label alpelisib use.
What does U.S. Patent 11,433,059 protect?
The patent claims a treatment method requiring the use of BYL719 in a defined PROS patient population. The central independent claim requires all of the following:
- The patient has a PROS disorder.
- The disorder involves overgrowth of multiple organs or tissues.
- The overgrowth is caused by a somatic mosaic mutation.
- The patient is identified as suffering from the disorder.
- BYL719 is administered orally.
- The amount is therapeutically effective.
- Treatment reverses the overgrowth.
- The PROS disorder is not responsive to rapamycin.
The patent therefore does not broadly claim every use of alpelisib, every patient with a PIK3CA mutation, or every treatment of a single-organ overgrowth condition. It claims a narrower clinical-use population with specified genetic, phenotypic, treatment-history, route-of-administration, and outcome limitations.
Core claim architecture
| Claim group |
Principal subject matter |
Key limitations |
| Claims 1-7 |
Treatment of PROS |
Multi-organ or multi-tissue overgrowth, somatic mosaic mutation, oral BYL719, rapamycin nonresponse |
| Claims 2-3 |
Specific PROS disorders |
CLOVES syndrome and Klippel-Trenaunay syndrome |
| Claims 4, 16 |
Dose range |
25-250 mg or 0.5-6 mg/kg under claim 4; 15-500 mg or 0.3-12 mg/kg under claim 16 |
| Claims 5-7, 9-11 |
Age-based starting doses |
Adults: at least 250 mg/day; children: at least 50 mg/day; infants: at least 25 mg/day |
| Claims 8, 12-13 |
Symptom-reversal treatment |
Broad symptom and disease lists, including CLOVES syndrome and Klippel-Trenaunay syndrome |
| Claims 14-15 |
Fixed starting doses |
Adults: 250 mg/day; children: 50 mg/day |
How broad is claim 1 of Patent 11,433,059?
Claim 1 has substantial therapeutic breadth but significant cumulative limitations. It covers a treatment method for PROS involving multiple tissues or organs, rather than a particular anatomical site or symptom. The claim is potentially relevant to systemic or extensive manifestations such as limb hypertrophy, vascular malformations, adipose overgrowth, scoliosis, lymphatic abnormalities, and visceral involvement.
The most important limiting language is:
- "caused by a somatic mosaic mutation";
- "overgrowth of multiple organs or tissues";
- "not responsive to treatment with rapamycin"; and
- "reverses said overgrowth."
These limitations create both infringement value and validity risk.
Somatic mosaic mutation requirement
PROS disorders are commonly associated with postzygotic activating mutations in the PIK3CA gene. Because the mutation may be present only in affected tissue, detection can depend on the biopsy site, assay sensitivity, and variant allele frequency.
For infringement purposes, a generic or physician may argue that the claim is not met if:
- no somatic mosaic PIK3CA mutation is documented;
- the mutation is detected constitutionally rather than mosaicly;
- the overgrowth is not shown to be caused by the identified mutation; or
- the patient is treated based on clinical diagnosis without genetic confirmation.
The patent holder would likely focus on the clinical and molecular record rather than on the product label alone. A treatment protocol that specifically requires genetic confirmation of PIK3CA mosaicism creates a stronger infringement case than broad empiric treatment.
Multiple-organ or multi-tissue overgrowth
This limitation separates the claims from treatment of an isolated vascular lesion or localized overgrowth. The phrase can cover overgrowth involving multiple tissue types within one anatomical region, depending on claim construction, but the literal scope is stronger where the record shows more than one affected organ or tissue.
Potential disputes include whether the following qualify:
- one limb containing adipose, vascular, and skeletal abnormalities;
- a single vascular malformation with secondary edema;
- localized overgrowth with systemic symptoms;
- bilateral or multifocal lesions;
- a syndrome diagnosis without documented current overgrowth in multiple tissues.
The specification and prosecution history would be important in resolving whether "multiple organs or tissues" requires multiple organs, multiple tissue classes, or either formulation.
Rapamycin nonresponse
The rapamycin limitation is a material narrowing element. It requires the relevant PROS disorder to be "not responsive to treatment with rapamycin." The claim does not expressly define:
- the rapamycin dose;
- treatment duration;
- the clinical endpoint;
- whether partial response qualifies as nonresponse;
- whether intolerance or discontinuation qualifies;
- whether prior rapamycin exposure is mandatory; or
- whether nonresponse must be documented before alpelisib treatment.
A patient who never received rapamycin may present a substantial noninfringement argument unless the patent or prosecution record supports a broader interpretation. A patient who discontinued rapamycin for toxicity may also fall outside the ordinary meaning of "not responsive" if the evidence does not show pharmacologic failure.
This limitation may materially reduce the practical scope of claim 1 because FDA-approved Vijoice treatment is not necessarily limited to patients who failed rapamycin.
What disorders and symptoms are covered?
Claims 2, 3, 12, and 13 expressly identify CLOVES syndrome and Klippel-Trenaunay syndrome. Claim 8 expands the claimed disease population to several PROS phenotypes.
Expressly identified PROS disorders
| Disorder or phenotype |
Claim coverage |
| Fibroadipose overgrowth |
Claim 8 |
| Megalencephaly-capillary malformation syndrome |
Claim 8 |
| CLOVES syndrome |
Claims 2, 8, 12 |
| Klippel-Trenaunay syndrome |
Claims 3, 8, 13 |
| Hemihyperplasia-multiple lipomatosis |
Claim 8 |
| Lymphatic, capillary, venous, and combined malformations |
Claim 8 |
| Epidermal nevi and skeletal or spinal anomalies |
Claim 8 |
Claim 8 also identifies symptoms and manifestations including limb hypertrophy, vascular tumors, edema, venous dilation, scoliosis, lymphatic malformation, muscle hypertrophy, dysregulated adipose tissue, kidney dysfunction, liver steatosis, cardiac enlargement, proteinuria, paraplegia, and loss of bladder control.
The list is drafted as a closed "selected from the group consisting of" limitation. An accused treatment generally must address at least one listed symptom, although the claim also requires treatment of a plurality of symptoms.
What dosing regimens are covered?
The patent contains overlapping dose ranges and age-specific starting-dose claims.
| Patient group |
Claimed starting dose |
| Adults |
At least 250 mg daily |
| Children |
At least 50 mg daily |
| Infants |
At least 25 mg daily |
| General dose range |
15-500 mg or 0.3-12 mg/kg |
| Claim 4 range |
25-250 mg or 0.5-6 mg/kg |
The fixed-dose claims are commercially important because the Vijoice label uses age- and weight-related dosing concepts. A regimen beginning at 250 mg daily in an adult, 50 mg daily in a child, or 25 mg daily in an infant may implicate claims 5-7, 9-11, 14, or 15, provided the disease and response limitations are also satisfied.
The ranges are not interchangeable in every case. A dose of 300 mg daily may fall within the 15-500 mg range but outside the 25-250 mg range. A weight-based dose must be evaluated independently against the applicable mg/kg range.
When does Patent 11,433,059 expire?
The patent issued on September 6, 2022. Its effective expiration depends on the earliest effective nonprovisional or PCT filing date, patent-term adjustment, terminal disclaimers, and any patent-term extension.
The ordinary statutory term for a U.S. utility patent is 20 years from the relevant earliest nonprovisional filing date, subject to adjustment under 35 U.S.C. §154 and extension under 35 U.S.C. §156. A reliable expiration date therefore requires review of the patent front page, continuity data, Patent Center records, and any Orange Book listing.
The patent should be treated as a long-dated method-of-use right extending into the mid-2030s unless the official record shows a different term. The basic alpelisib composition patent and the PROS method patent should be analyzed separately because expiration of the composition patent does not necessarily eliminate infringement risk under a later method-of-use patent.
What is the FDA and Orange Book relevance?
Alpelisib is marketed as Piqray for certain PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer and as Vijoice for severe manifestations of PROS.
The FDA approved Vijoice for adults and pediatric patients aged two years and older with severe manifestations of PROS requiring systemic therapy. The FDA approval is relevant because it establishes a labeled commercial use that overlaps materially with the claimed PROS population, although the patent claims contain additional limitations, especially rapamycin nonresponse and reversal of multi-organ or multi-tissue overgrowth.[1]
The Orange Book analysis should distinguish:
- patents listed against the Vijoice NDA;
- patents listed against the Piqray NDA;
- use codes covering PROS;
- formulation or drug-product patents;
- method-of-treatment patents;
- patent term and pediatric exclusivity;
- any patent delisting or litigation activity.
A method-of-use patent can create Paragraph IV exposure for an ANDA applicant if the proposed labeling or product use is directed to the patented indication. Under a section viii statement, an applicant may attempt to carve out the patented use, but the feasibility depends on the approved labeling, prescribing information, and whether the remaining label still encourages the patented method.
Are generic alpelisib products a biosimilar risk?
No. Alpelisib is a chemically synthesized small molecule. A competing product would normally use the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.
The commercial risk is therefore a generic-launch and Paragraph IV risk, not a biosimilar-substitution risk. Relevant barriers include:
- the active-ingredient patent estate;
- formulation and solid-state patents;
- method-of-use patents;
- Vijoice and Piqray labeling;
- controlled clinical-use restrictions;
- pediatric dosing claims;
- potential induced-infringement theories;
- FDA approval timing and 30-month stays.
Because Patent 11,433,059 claims treatment methods, an ANDA applicant could seek a label carve-out for PROS. That strategy would be more difficult if the generic label, risk-management materials, promotional activities, or prescribing information still direct physicians toward the claimed patient population.
How strong is the patent estate?
Patent 11,433,059 has moderate-to-strong commercial relevance but narrower literal scope than a composition patent.
Strengths
- It covers the clinically important PROS indication.
- It names alpelisib directly through the BYL719 designation.
- It includes commercially meaningful adult and pediatric dosing claims.
- It covers major PROS phenotypes, particularly CLOVES syndrome and Klippel-Trenaunay syndrome.
- It is directed to a rare-disease population with limited systemic-treatment alternatives.
- The claim set includes both broad disease claims and narrower fixed-dose claims.
Weaknesses
- Rapamycin nonresponse may be difficult to prove and may exclude first-line patients.
- "Reverses" may require objective clinical evidence rather than symptom stabilization.
- "Multiple organs or tissues" may generate claim-construction disputes.
- A generic applicant may attempt a section viii carve-out.
- The claims are vulnerable if the treatment record lacks molecular confirmation of a somatic mosaic mutation.
- The patent does not prevent all non-infringing uses of alpelisib for unrelated cancers or non-PROS conditions.
The strongest enforcement scenario is a labeled or promoted use of alpelisib for genetically confirmed PROS patients with extensive multi-tissue overgrowth after documented rapamycin failure, using the claimed age-specific doses.
What patent litigation and Paragraph IV risks exist?
The principal litigation risk would arise if a generic alpelisib applicant seeks approval for an indication overlapping PROS or uses a label that encourages treatment of the claimed population. A patent owner may assert:
- direct infringement by use;
- induced infringement based on labeling or promotion;
- contributory infringement in limited circumstances;
- infringement of separate formulation or drug-product patents.
A Paragraph IV notice involving Patent 11,433,059 could trigger a Hatch-Waxman action within 45 days and potentially a 30-month FDA approval stay, subject to statutory exceptions and the patent's listing status. The commercial effect would depend on whether the patent is listed for the relevant NDA, whether the ANDA applicant has carved out the PROS indication, and whether other alpelisib patents remain in force.
No litigation or settlement outcome should be inferred solely from the existence of the patent. The controlling sources are the FDA Orange Book, Paragraph IV notice, district-court docket, Federal Circuit decisions, and any publicly filed settlement agreement.
How does Patent 11,433,059 compare with other alpelisib rights?
| Right type |
Typical subject matter |
Relevance to generic entry |
| Composition patent |
Alpelisib chemical entity |
Broadest product protection |
| Solid-state or formulation patent |
Polymorphs, tablets, excipients, stability |
May block the same commercial product |
| Method-of-use patent |
PROS or cancer treatment |
Can be addressed through label carve-out |
| Regulatory exclusivity |
New indication or pediatric approval |
Delays approval independently of patent term |
| Patent 11,433,059 |
PROS treatment with BYL719 |
Directly targets alpelisib use in PROS |
Patent 11,433,059 is more commercially focused than a general alpelisib composition patent. Its value is concentrated in Vijoice and in treatment protocols involving severe PROS manifestations. Its enforcement strength depends heavily on how Novartis and prescribers define the labeled patient population.
What generic launch scenarios exist?
Scenario 1: Full-label generic launch
A generic applicant seeks an indication covering PROS and cancer uses. This creates the highest infringement and litigation exposure because the label may directly read on the patent claims.
Scenario 2: Section viii carve-out
The applicant removes PROS language and seeks approval for non-PROS indications, such as PIK3CA-mutated breast cancer. This may avoid literal label infringement but does not eliminate risk from physician use, promotional conduct, or other listed patents.
Scenario 3: Paragraph IV invalidity challenge
The applicant argues that the claims are invalid for lack of novelty, obviousness, written-description failure, enablement, indefiniteness, or inadequate support for the full disease and symptom scope.
Scenario 4: Noninfringement based on rapamycin status
The applicant argues that the proposed use does not require treatment of rapamycin-refractory patients or that the patient population does not satisfy the claimed mosaic-mutation and multi-tissue limitations.
Key Takeaways
- Patent 11,433,059 is a PROS-specific alpelisib method patent.
- Its principal commercial target is Vijoice use in severe PROS.
- The claims require oral BYL719, somatic mosaic mutation, multi-organ or multi-tissue overgrowth, and rapamycin nonresponse.
- CLOVES syndrome and Klippel-Trenaunay syndrome are expressly covered.
- Adult, pediatric, infant, fixed-dose, and weight-based regimens are claimed.
- The patent does not cover all alpelisib use or all PIK3CA-mutated diseases.
- Generic risk is based on the ANDA and Paragraph IV framework, not biosimilar substitution.
- The most important claim vulnerabilities concern rapamycin nonresponse, proof of mutation causation, the meaning of "multiple organs or tissues," and the requirement that treatment "reverse" overgrowth.
- The patent should be assessed together with alpelisib composition, formulation, Orange Book, regulatory-exclusivity, and litigation records.
FAQs About U.S. Patent 11,433,059
Does Patent 11,433,059 cover Piqray use in breast cancer?
No. The supplied claims are directed to PROS treatment. They do not claim treatment of breast cancer, although separate alpelisib patents and regulatory rights may apply to Piqray.
Does the patent require prior rapamycin treatment?
The claims require that the PROS disorder is not responsive to rapamycin. Whether this requires documented prior treatment depends on claim construction and the patent record, but the limitation creates a meaningful issue for patients who have never received rapamycin.
Can a generic sell alpelisib for cancer while excluding PROS?
Potentially. A section viii label carve-out may reduce infringement risk if the approved labeling and actual conduct do not encourage the patented PROS use.
Are Vijoice and Piqray protected by the same patents?
Not necessarily. The products contain the same active ingredient, but Orange Book listings, use codes, approved indications, formulation rights, and regulatory exclusivities may differ by NDA.
Does the patent cover topical or injectable alpelisib?
The claims expressly require oral administration. A non-oral product would generally not satisfy that limitation, although separate claims or other patents could create independent risk.
References
- U.S. Food and Drug Administration. (2022). FDA approves alpelisib for PIK3CA-related overgrowth spectrum.
- U.S. Food and Drug Administration. (2024). Vijoice (alpelisib) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2022). United States Patent No. 11,433,059.
- U.S. Congress. (2011). Leahy-Smith America Invents Act, 35 U.S.C. §§ 154, 271, 282.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations, 21 C.F.R. § 314.94.
